{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T05:25:02Z","timestamp":1761110702754,"version":"3.37.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-024-00701-y","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T10:24:46Z","timestamp":1725963886000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Complete morphologic response to gilteritinib in ALK-rearranged acute myeloid leukemia"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4272-312X","authenticated-orcid":false,"given":"Jacob J.","family":"Adashek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max","family":"Brodsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark J.","family":"Levis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,10]]},"reference":[{"key":"701_CR1","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner, H. et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140, 1345\u20131377 (2022).","journal-title":"Blood"},{"key":"701_CR2","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/s41375-018-0019-y","volume":"32","author":"A Tefferi","year":"2018","unstructured":"Tefferi, A. et al. Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. Leukemia 32, 1200\u20131210 (2018).","journal-title":"Leukemia"},{"key":"701_CR3","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1182\/blood-2006-12-062125","volume":"110","author":"A Theocharides","year":"2007","unstructured":"Theocharides, A. et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 110, 375\u2013379 (2007).","journal-title":"Blood"},{"key":"701_CR4","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1634\/theoncologist.2016-0488","volume":"22","author":"JS Ross","year":"2017","unstructured":"Ross, J. S. et al. ALK fusions in a wide variety of tumor types respond to anti-ALK targeted therapy. Oncologist 22, 1444\u20131450 (2017).","journal-title":"Oncologist"},{"key":"701_CR5","unstructured":"Kaseb H., Mukkamalla S. K. R., Rajasurya V. Anaplastic Large Cell Lymphoma. StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Shiva Kumar Mukkamalla declares no relevant financial relationships with ineligible companies. Disclosure: Venkat Rajasurya declares no relevant financial relationships with ineligible companies (2024)."},{"key":"701_CR6","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1182\/blood.V92.8.2688","volume":"92","author":"I Wlodarska","year":"1998","unstructured":"Wlodarska, I. et al. The cryptic inv(2)(p23q35) defines a new molecular genetic subtype of ALK-positive anaplastic large-cell lymphoma. Blood 92, 2688\u20132695 (1998).","journal-title":"Blood"},{"key":"701_CR7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s12185-013-1482-x","volume":"99","author":"Y Maesako","year":"2014","unstructured":"Maesako, Y. et al. inv(2)(p23q13)\/RAN-binding protein 2 (RANBP2)-ALK fusion gene in myeloid leukemia that developed in an elderly woman. Int. J. Hematol. 99, 202\u2013207 (2014).","journal-title":"Int. J. Hematol."},{"key":"701_CR8","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1158\/0008-5472.CAN-14-1576","volume":"75","author":"JE Maxson","year":"2015","unstructured":"Maxson, J. E. et al. Therapeutically targetable ALK mutations in leukemia. Cancer Res. 75, 2146\u20132150 (2015).","journal-title":"Cancer Res."},{"key":"701_CR9","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.critrevonc.2018.11.004","volume":"134","author":"L Kassem","year":"2019","unstructured":"Kassem, L. et al. Safety issues with the ALK inhibitors in the treatment of NSCLC: A systematic review. Crit. Rev. Oncol. Hematol. 134, 56\u201364 (2019).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"701_CR10","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl, A. E. et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N. Engl. J. Med. 381, 1728\u20131740 (2019).","journal-title":"N. Engl. J. Med."},{"key":"701_CR11","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1182\/blood-2016-10-745133","volume":"129","author":"LY Lee","year":"2017","unstructured":"Lee, L. Y. et al. Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor. Blood 129, 257\u2013260 (2017).","journal-title":"Blood"},{"key":"701_CR12","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1038\/leu.2014.166","volume":"28","author":"Y Maesako","year":"2014","unstructured":"Maesako, Y. et al. Reduction of leukemia cell burden and restoration of normal hematopoiesis at 3 months of crizotinib treatment in RAN-binding protein 2 (RANBP2)-anaplastic lymphoma kinase (ALK) acute myeloid leukemia. Leukemia 28, 1935\u20131937 (2014).","journal-title":"Leukemia"},{"key":"701_CR13","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cancergen.2015.01.003","volume":"208","author":"K Takeoka","year":"2015","unstructured":"Takeoka, K., Okumura, A., Maesako, Y., Akasaka, T. & Ohno, H. Crizotinib resistance in acute myeloid leukemia with inv(2)(p23q13)\/RAN binding protein 2 (RANBP2) anaplastic lymphoma kinase (ALK) fusion and monosomy 7. Cancer Genet. 208, 85\u201390 (2015).","journal-title":"Cancer Genet"},{"key":"701_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.52","volume":"6","author":"A Hayashi","year":"2016","unstructured":"Hayashi, A. et al. Crizotinib treatment for refractory pediatric acute myeloid leukemia with RAN-binding protein 2-anaplastic lymphoma kinase fusion gene. Blood Cancer J. 6, e456 (2016).","journal-title":"Blood Cancer J."},{"key":"701_CR15","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.3390\/biomedicines11071842","volume":"11","author":"M Shekar","year":"2023","unstructured":"Shekar, M. et al. ALK fusion in an adolescent with acute myeloid leukemia: A case report and review of the literature. Biomedicines 11, 1842 (2023).","journal-title":"Biomedicines"},{"key":"701_CR16","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury, J. D. et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia 36, 1703\u20131719 (2022).","journal-title":"Leukemia"},{"key":"701_CR17","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/gcc.10177","volume":"37","author":"Z Ma","year":"2003","unstructured":"Ma, Z. et al. Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 37, 98\u2013105 (2003).","journal-title":"Genes Chromosomes Cancer"},{"key":"701_CR18","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo, C. D. et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N. Engl. J. Med. 383, 617\u2013629 (2020).","journal-title":"N. Engl. J. Med."},{"key":"701_CR19","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.eururo.2018.03.032","volume":"74","author":"SK Pal","year":"2018","unstructured":"Pal, S. K. et al. Responses to alectinib in ALK-rearranged papillary renal cell carcinoma. Eur. Urol. 74, 124\u2013128 (2018).","journal-title":"Eur. Urol."},{"key":"701_CR20","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1056\/NEJMc2101264","volume":"385","author":"A Bagchi","year":"2021","unstructured":"Bagchi, A. et al. Lorlatinib in a child with ALK-fusion-positive high-grade glioma. N. Engl. J. Med. 385, 761\u2013763 (2021).","journal-title":"N. Engl. J. Med"},{"key":"701_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00378-9","volume":"7","author":"JJ Adashek","year":"2023","unstructured":"Adashek, J. J., Sapkota, S., de Castro Luna, R. & Seiwert, T. Y. Complete response to alectinib in ALK-fusion metastatic salivary ductal carcinoma. NPJ Precis Oncol. 7, 36 (2023).","journal-title":"NPJ Precis Oncol."},{"key":"701_CR22","doi-asserted-by":"publisher","first-page":"344","DOI":"10.3390\/cancers15020344","volume":"15","author":"K Kim","year":"2023","unstructured":"Kim, K., Ong, F. & Sasaki, K. Current understanding of DDX41 mutations in myeloid neoplasms. Cancers (Basel) 15, 344 (2023).","journal-title":"Cancers (Basel)"},{"key":"701_CR23","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.ccell.2015.03.017","volume":"27","author":"C Polprasert","year":"2015","unstructured":"Polprasert, C. et al. Inherited and somatic defects in DDX41 in myeloid neoplasms. Cancer Cell 27, 658\u2013670 (2015).","journal-title":"Cancer Cell"},{"key":"701_CR24","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1182\/blood.2022018221","volume":"141","author":"H Makishima","year":"2023","unstructured":"Makishima, H. et al. Germ line DDX41 mutations define a unique subtype of myeloid neoplasms. Blood 141, 534\u2013549 (2023).","journal-title":"Blood"},{"key":"701_CR25","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1182\/blood.2021015328","volume":"140","author":"N Duployez","year":"2022","unstructured":"Duployez, N. et al. Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study. Blood 140, 756\u2013768 (2022).","journal-title":"Blood"},{"key":"701_CR26","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1158\/1078-0432.CCR-22-2036","volume":"29","author":"TH Patel","year":"2023","unstructured":"Patel, T. H. et al. FDA approval summary: Pemigatinib for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or other rearrangement. Clin. Cancer Res. 29, 838\u2013842 (2023).","journal-title":"Clin. Cancer Res"},{"key":"701_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.112984","volume":"191","author":"L Brugieres","year":"2023","unstructured":"Brugieres, L. et al. Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcSe-crizotinib trial. Eur. J. Cancer 191, 112984 (2023).","journal-title":"Eur. J. Cancer"},{"key":"701_CR28","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMc2402419","volume":"390","author":"L Veleanu","year":"2024","unstructured":"Veleanu, L., Lamant, L. & Sibon, D. Therapeutic strategy project for adult AA. Brigatinib in ALK-positive ALCL after failure of brentuximab vedotin. N. Engl. J. Med. 390, 2129\u20132130 (2024).","journal-title":"N. Engl. J. Med"},{"key":"701_CR29","doi-asserted-by":"publisher","first-page":"4540","DOI":"10.1111\/cas.14671","volume":"111","author":"R Fukano","year":"2020","unstructured":"Fukano, R. et al. Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial. Cancer Sci. 111, 4540\u20134547 (2020).","journal-title":"Cancer Sci."},{"key":"701_CR30","doi-asserted-by":"publisher","first-page":"e2200536","DOI":"10.1200\/PO.22.00536","volume":"7","author":"B Wirk","year":"2023","unstructured":"Wirk, B., Malysz, J., Choi, E. & Songdej, N. Lorlatinib induces rapid and durable response in refractory anaplastic lymphoma kinase-positive large B-cell lymphoma. JCO Precis Oncol. 7, e2200536 (2023).","journal-title":"JCO Precis Oncol."},{"key":"701_CR31","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1016\/S1470-2045(21)00536-2","volume":"22","author":"M Fischer","year":"2021","unstructured":"Fischer, M. et al. Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: An open-label, multicentre, phase 1, dose-escalation and dose-expansion study. Lancet Oncol. 22, 1764\u20131776 (2021).","journal-title":"Lancet Oncol."},{"key":"701_CR32","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1158\/1535-7163.MCT-21-0329","volume":"20","author":"JJ Adashek","year":"2021","unstructured":"Adashek, J. J. et al. Hallmarks of RET and co-occuring genomic alterations in RET-aberrant cancers. Mol. Cancer Ther. 20, 1769\u20131776 (2021).","journal-title":"Mol. Cancer Ther."},{"key":"701_CR33","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1158\/1541-7786.MCR-20-0738","volume":"19","author":"S Kuravi","year":"2021","unstructured":"Kuravi, S. et al. Preclinical evaluation of gilteritinib on NPM1-ALK-driven anaplastic large cell lymphoma cells. Mol. Cancer Res. 19, 913\u2013920 (2021).","journal-title":"Mol. Cancer Res."},{"key":"701_CR34","doi-asserted-by":"publisher","first-page":"4343","DOI":"10.1111\/cas.15958","volume":"114","author":"C Ando","year":"2023","unstructured":"Ando, C. et al. Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK-rearranged non-small cell lung cancer. Cancer Sci. 114, 4343\u20134354 (2023).","journal-title":"Cancer Sci."},{"key":"701_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21396-w","volume":"12","author":"H Mizuta","year":"2021","unstructured":"Mizuta, H. et al. Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer. Nat. Commun. 12, 1261 (2021).","journal-title":"Nat. Commun."},{"key":"701_CR36","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.73","volume":"13","author":"BA Cohen-Kurzrock","year":"2016","unstructured":"Cohen-Kurzrock, B. A., Cohen, P. R. & Kurzrock, R. Health policy: The right to try is embodied in the right to die. Nat. Rev. Clin. Oncol. 13, 399\u2013400 (2016).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"701_CR37","first-page":"614","volume":"16","author":"V Tateo","year":"2023","unstructured":"Tateo, V. et al. Agnostic approvals in oncology: Getting the right drug to the right patient with the right genomics. Pharm. (Basel) 16, 614 (2023).","journal-title":"Pharm. (Basel)"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-024-00701-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-024-00701-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-024-00701-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T22:03:19Z","timestamp":1726005799000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-024-00701-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,10]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["701"],"URL":"https:\/\/doi.org\/10.1038\/s41698-024-00701-y","relation":{},"ISSN":["2397-768X"],"issn-type":[{"type":"electronic","value":"2397-768X"}],"subject":[],"published":{"date-parts":[[2024,9,10]]},"assertion":[{"value":"26 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.J.A. serves on the advisory board of CureMatch Inc. and serves as a consultant for datma. M.B. has no relevant competing interests to disclose. M.J.L. declares Astellas (Laboratory Service Agreement) and Astellas, Daiichi-Sankyo, Abbvie, Bristol Myers Squibb, Amgen, Glaxo-Smith Kline, Jazz, Schroedinger, Syndax, Takeda (Consultant\/Advisor\/clinical trial funding).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"197"}}